The FDA and EMA approved Eli Lilly's Mounjaro (tirzepatide) peptide injection in May and July 2022, respectively. It is important to note that the identity of this peptide drug is a special GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) dual receptor agonist for the treatment of type II diabetes. Tirzepatide targets both GLP-1 and GIP receptors and is the first FDA-approved new drug. GLP-1/GIP dual receptor agonists, which exhibit better glycemic control and weight loss than selective GLP-1 receptor agonists. The amino acid sequence of tirzepatide is d on the endogenous GIP sequence, and the pharmacological effect on the GLP-1 receptor is comparable to that of endogenous GIP; The long half-life of tirzepatide of about 5 days can be achieved by dosing once a week. Tirzepatide was approved by the FDA on May 13, 2022 for the treatment of type 2 diabetes in adults, making it the first and only GIP and GLP-1 receptor agonist. Although tirzepatide is not currently available as a weight loss drug, it seems that it is only a matter of time from the current situation. Phase III Clinical SURMOUNT-1 (NCT04184622): Efficacy and Safety of tirzepatide Weekly in Participants With Obese or Overweight with Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial Expected to be completed in the first half of 2024.